Simon Tiberi
A5082235034- Tuberculosis Research and Epidemiology
- Infectious Diseases and Tuberculosis
- Mycobacterium research and diagnosis
- Diagnosis and treatment of tuberculosis
- Pneumocystis jirovecii pneumonia detection and treatment
- Pneumonia and Respiratory Infections
- Antibiotics Pharmacokinetics and Efficacy
- COVID-19 Clinical Research Studies
- Antimicrobial Resistance in Staphylococcus
- Orthopedic Infections and Treatments
- Cancer therapeutics and mechanisms
- HIV/AIDS drug development and treatment
- Pharmaceutical studies and practices
- Antibiotic Resistance in Bacteria
- Infective Endocarditis Diagnosis and Management
- Cardiac electrophysiology and arrhythmias
- Biosimilars and Bioanalytical Methods
- COVID-19 and healthcare impacts
- Long-Term Effects of COVID-19
- Hematological disorders and diagnostics
- HIV/AIDS Research and Interventions
- Pharmacological Effects and Toxicity Studies
- Lung Cancer Diagnosis and Treatment
- Computational Drug Discovery Methods
- SARS-CoV-2 and COVID-19 Research
Queen Mary University of London
2017-2024
Barts Health NHS Trust
2015-2023
Royal London Hospital
2015-2023
National Health Service
2018-2023
Newcastle University
2023
The Royal Free Hospital
2022
University College London
2022
Newham University Hospital
2015-2021
University of Birmingham
2021
Research Center Borstel - Leibniz Lung Center
2019
The October 2020 Global TB report reviews control strategies and United Nations (UN) targets set in the political declaration at September 2018 UN General Assembly high-level meeting on held New York. Progress care prevention has been very slow. In 2019, remained most common cause of death from a single infectious pathogen. Globally, an estimated 10.0 million people developed disease there were 1.2 deaths among HIV-negative additional 208, 000 living with HIV. Adults accounted for 88%...
Large studies on bedaquiline used to treat multidrug-resistant (MDR-) and extensively drug-resistant tuberculosis (XDR-TB) are lacking. This study aimed evaluate the safety effectiveness of bedaquiline-containing regimens in a large, retrospective, observational conducted 25 centres 15 countries five continents.428 culture-confirmed MDR-TB cases were analysed (61.5% male; 22.1% HIV-positive, 45.6% XDR-TB). admitted hospital for median (interquartile range (IQR)) 179 (92-280) days exposed 168...
BackgroundTackling tuberculosis requires testing and treatment of latent in high-risk groups. The aim this study was to estimate the predictive values tuberculin skin test (TST) two interferon-γ release assays (IGRAs) for development active groups—ie, people recent contact with cases from high-burden countries.MethodIn prospective cohort study, we recruited participants 54 centres (eg, clinics, community settings) London, Birmingham, Leicester UK. Participants were eligible if they aged 16...
The World Health Organization (WHO) recommends that countries implement pharmacovigilance and collect information on active drug safety monitoring (aDSM) management of adverse events.The aim this prospective study was to evaluate the frequency severity events anti-tuberculosis (TB) drugs in a cohort consecutive TB patients treated with new (i.e. bedaquiline, delamanid) repurposed clofazimine, linezolid) drugs, based WHO aDSM project. Adverse were collected prospectively after attribution...
Abstract New tuberculosis treatments are needed to address drug resistance, lengthy treatment duration and adverse reactions of available agents. GSK3036656 (ganfeborole) is a first-in-class benzoxaborole inhibiting the Mycobacterium leucyl-tRNA synthetase. Here, in this phase 2a, single-center, open-label, randomized trial, we assessed early bactericidal activity (primary objective) safety pharmacokinetics (secondary objectives) ganfeborole participants with untreated,...
The current methods available to diagnose antimicrobial-resistant Mycobacterium tuberculosis infections require a positive culture or only test limited number of resistance-associated mutations. A rapid accurate identification antimicrobial resistance enables the prompt initiation effective treatment.
Clinical experience on meropenem–clavulanate to treat tuberculosis (TB) is anecdotal (according case reports 10 patients). The aim of our case–control study was evaluate the contribution when added linezolid-containing regimens in terms efficacy and safety/tolerability treating multidrug-resistant (MDR) extensively drug-resistant (XDR) TB cases after 3 months second-line treatment. 37 with MDR-/XDR-TB were prescribed (3 g daily dose) addition a regimen (dosage range 300–1200 mg·day −1 ),...
The classification of anti-tuberculosis (TB) drugs is important as it helps the clinician to build an appropriate anti-TB regimen for multidrug-resistant (MDR) and extensively drug-resistant (XDR) TB cases that do not fulfil criteria shorter MDR-TB regimen. World Health Organization (WHO) has recently approved a revision new based on current evidence each drug. In previous WHO guidelines, choice was efficacy toxicity in step-down manner, from group 1 first-line groups 2-5 second-line drugs,...
No large study has ever evaluated the efficacy, safety and tolerability of meropenem/clavulanate to treat multidrug- extensively drug-resistant tuberculosis (MDR- XDR-TB). The aim this observational was evaluate therapeutic contribution, effectiveness, profile added a background regimen when treating MDR- XDR-TB cases. Patients treated with meropenem/clavulanate-containing (n=96) showed greater drug resistance than those exposed meropenem/clavulanate-sparing (n=168): in former group more...
Drug-resistant Mycobacterium tuberculosis is challenging elimination of (TB). We evaluated risk factors for TB and levels second-line drug resistance in M. patients Europe with multidrug-resistant (MDR) TB. A total 380 MDR 376 non-MDR were enrolled at 23 centers 16 countries during 2010-2011. 52.4% had never been treated TB, which suggests primary transmission tuberculosis. At initiation treatment 59.7% strains tested resistant to pyrazinamide, 51.1% ≥1 drug, 26.6% injectable drugs, 17.6%...
( BMJ . 2020;370:m3320) Since its onset, the novel coronavirus disease (COVID-19) caused by SARS-CoV-2 has increased morbidity and mortality worldwide. The pregnant population been of particular concern, as effects COVID-19 on this group their neonates during after pregnancy are unknown. Several large case series systematic reviews exist, however variance in method, testing duplicated data have yielded results that at times lack external validity become quickly outdated. primary goal study...
In May 2016, two cases of tick-borne encephalitis (TBE) were confirmed by serology (positive IgM and IgG antibodies against TBE virus (TBEV) in serum), with a possible link to raw milk cheese from goat farm region Baden-Württemberg, Germany not previously known as TBE-endemic. The outbreak investigation identified 32 consumers dairy products (29 consumers, one employee, owners) whom none had TBEV 3–8 weeks after consumption. Of the 27 notified State, reported consumption or suspected farm....
Non-tuberculous mycobacteria (NTM) are ubiquitous dwellers of environmental niches and an established cause natural nosocomial infections. The incidence NTM infections is rising owing to a growing population immunocompromised vulnerable individuals, complex medical surgical procedures, as well increased awareness diagnostic capabilities. prevalence different varies between continents, regions, countries. true global burden pulmonary extrapulmonary disease unknown estimates subject under...
Tuberculosis (TB) preventive therapy (TPT) decreases the risk of developing TB disease and its associated morbidity mortality. The aim these clinical standards is to guide assessment, management infection (TBI) implementation TPT.